{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Multitask Learning\n",
    "\n",
    "Use a single shared representation to predict gender and phase 2"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Load Embeddings and Abstracts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "%store -r embeddings_info\n",
    "\n",
    "abstracts = embeddings_info['abstracts']\n",
    "abstracts_padded = embeddings_info['abstracts_padded']\n",
    "embeddings = embeddings_info['embeddings']\n",
    "word_dim = embeddings_info['word_dim']\n",
    "word2idx, idx2word = embeddings_info['word2idx'], embeddings_info['idx2word']\n",
    "maxlen = embeddings_info['maxlen']\n",
    "vocab_size = embeddings_info['vocab_size']"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Load Labels"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "%store -r pruned_dataset binarized_dataset\n",
    "\n",
    "ys = np.array(binarized_dataset).T\n",
    "\n",
    "from support import classinfo_generator, produce_labels\n",
    "\n",
    "labels = pruned_dataset.columns.tolist()\n",
    "class_info = list(classinfo_generator(pruned_dataset))\n",
    "class_names, class_sizes = zip(*class_info)\n",
    "class_names = {label: classes for label, classes in zip(labels, class_names)}\n",
    "\n",
    "data = dict(produce_labels(labels, class_sizes, ys))\n",
    "data.update({'input': abstracts_padded})\n",
    "\n",
    "val_dict = {label: y_row for label, y_row in zip(labels, ys)}\n",
    "val_dict.update({'input': abstracts_padded})"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Hyperparameters"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "nb_filter = 20\n",
    "filter_length = 2\n",
    "hidden_dims = 32\n",
    "nb_epoch = 35\n",
    "batch_size = 10"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Define Model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "collapsed": false,
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Using Theano backend.\n",
      "/home/ebanner/.anaconda/envs/py27/lib/python2.7/site-packages/theano/tensor/signal/downsample.py:5: UserWarning: downsample module has been moved to the pool module.\n",
      "  warnings.warn(\"downsample module has been moved to the pool module.\")\n"
     ]
    }
   ],
   "source": [
    "from keras.models import Graph\n",
    "from keras.layers.core import Dense, Dropout, Activation, Flatten\n",
    "from keras.layers.embeddings import Embedding\n",
    "from keras.layers.convolutional import Convolution1D, MaxPooling1D\n",
    "\n",
    "model = Graph()\n",
    "model.add_input(name='input', input_shape=[maxlen], dtype='int') # dtype='int' is 100% necessary for some reason!\n",
    "model.add_node(Embedding(input_dim=vocab_size, output_dim=word_dim, weights=[embeddings], input_length=maxlen, trainable=False),\n",
    "               name='embedding', input='input')\n",
    "model.add_node(Dropout(0.25), name='dropout1', input='embedding')\n",
    "\n",
    "model.add_node(Convolution1D(nb_filter=nb_filter,\n",
    "                             filter_length=filter_length,\n",
    "                             activation='relu'),\n",
    "              name='conv',\n",
    "              input='dropout1')\n",
    "model.add_node(MaxPooling1D(pool_length=maxlen-1), name='pool', input='conv') # non-maximum suppression\n",
    "model.add_node(Flatten(), name='flat', input='pool')\n",
    "model.add_node(Dense(hidden_dims), name='z', input='flat')\n",
    "model.add_node(Activation('relu'), name='shared', input='z')\n",
    "model.add_node(Dropout(0.25), name='dropout2', input='shared')\n",
    "\n",
    "# Fork the graph and predict probabilities for each target from shared representation\n",
    "for label, num_classes in zip(labels, class_sizes):\n",
    "    model.add_node(Dense(output_dim=num_classes, activation='softmax'), name='{}_probs'.format(label), input='dropout2')\n",
    "    model.add_output(name=label, input='{}_probs'.format(label))\n",
    "\n",
    "model.compile(optimizer='rmsprop',\n",
    "              loss={label: 'categorical_crossentropy' for label in labels}) # CE for all the targets"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Define Callback"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "import keras\n",
    "\n",
    "class AccuracyCallback(keras.callbacks.Callback):\n",
    "    def __init__(self, validation_data, val_dict, batch_size, num_train, val_every):\n",
    "        \"\"\"Callback to compute accuracy during training\n",
    "        \n",
    "        Parameters\n",
    "        ----------\n",
    "        validation : dict of data expected by graph.predict()\n",
    "        val_dict : dict from labels to classes\n",
    "        batch_size : number of examples per batch\n",
    "        num_train : number of examples in training set\n",
    "        val_every : number of times to to validation during an epoch\n",
    "        \n",
    "        \"\"\"\n",
    "        self.validation_data = validation_data\n",
    "        self.val_dict = val_dict\n",
    "        self.num_batches_since_val = 0\n",
    "        num_minis_per_epoch = (num_train/batch_size) # number of minibatches per epoch\n",
    "        self.K = num_minis_per_epoch / val_every # number of batches to go before doing validation\n",
    "        \n",
    "        super(AccuracyCallback, self).__init__()\n",
    "        \n",
    "    def on_batch_end(self, batch, logs={}):\n",
    "        \"\"\"Do validation if it's been a while\n",
    "        \n",
    "        Specifically, \"\"\"\n",
    "        \n",
    "        if self.num_batches_since_val < self.K-1:\n",
    "            self.num_batches_since_val += 1\n",
    "            return\n",
    "            \n",
    "        predictions = self.model.predict(self.validation_data)\n",
    "        \n",
    "        print\n",
    "        for label, ys_pred in predictions.items():\n",
    "            print '{} accuracy:'.format(label), np.mean(ys_pred.argmax(axis=1) == self.val_dict[label])\n",
    "            \n",
    "        self.num_batches_since_val = 0"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Training"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {
    "collapsed": false,
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Train on 50 samples, validate on 50 samples\n",
      "Epoch 1/10\n",
      "24/50 [=============>................] - ETA: 0s - loss: 0.5628\n",
      "gender accuracy: 0.96\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "48/50 [===========================>..] - ETA: 0s - loss: 0.5856\n",
      "gender accuracy: 0.96\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "50/50 [==============================] - 3s - loss: 0.5701 - val_loss: 0.4096\n",
      "Epoch 00000: saving model to weights.hdf5\n",
      "Epoch 2/10\n",
      "18/50 [=========>....................] - ETA: 0s - loss: 0.6675\n",
      "gender accuracy: 0.96\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "42/50 [========================>.....] - ETA: 0s - loss: 0.5576\n",
      "gender accuracy: 0.98\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "50/50 [==============================] - 3s - loss: 0.5661 - val_loss: 0.4051\n",
      "Epoch 00001: saving model to weights.hdf5\n",
      "Epoch 3/10\n",
      "12/50 [======>.......................] - ETA: 0s - loss: 0.5332\n",
      "gender accuracy: 0.96\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "36/50 [====================>.........] - ETA: 0s - loss: 0.5268\n",
      "gender accuracy: 0.96\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "50/50 [==============================] - 3s - loss: 0.5702 - val_loss: 0.3945\n",
      "Epoch 00002: saving model to weights.hdf5\n",
      "Epoch 4/10\n",
      " 6/50 [==>...........................] - ETA: 0s - loss: 0.4074"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/ebanner/.anaconda/envs/py27/lib/python2.7/site-packages/keras/callbacks.py:67: UserWarning: Method on_batch_end() is slow compared to the batch update (0.350217). Check your callbacks.\n",
      "  % delta_t_median)\n",
      "/home/ebanner/.anaconda/envs/py27/lib/python2.7/site-packages/keras/callbacks.py:67: UserWarning: Method on_batch_end() is slow compared to the batch update (0.703228). Check your callbacks.\n",
      "  % delta_t_median)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "gender accuracy: 0.94\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "30/50 [=================>............] - ETA: 0s - loss: 0.4581\n",
      "gender accuracy: 0.96\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "48/50 [===========================>..] - ETA: 0s - loss: 0.5466\n",
      "gender accuracy: 0.96\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "50/50 [==============================] - 3s - loss: 0.5373 - val_loss: 0.3717\n",
      "Epoch 00003: saving model to weights.hdf5\n",
      "Epoch 5/10\n",
      "24/50 [=============>................] - ETA: 0s - loss: 0.7318\n",
      "gender accuracy: 0.96\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "48/50 [===========================>..] - ETA: 0s - loss: 0.5238\n",
      "gender accuracy: 0.96\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "50/50 [==============================] - 3s - loss: 0.5073 - val_loss: 0.3520\n",
      "Epoch 00004: saving model to weights.hdf5\n",
      "Epoch 6/10\n",
      "18/50 [=========>....................] - ETA: 0s - loss: 0.4753\n",
      "gender accuracy: 0.94\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "42/50 [========================>.....] - ETA: 0s - loss: 0.4395\n",
      "gender accuracy: 0.98\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "50/50 [==============================] - 3s - loss: 0.4913 - val_loss: 0.3501\n",
      "Epoch 00005: saving model to weights.hdf5\n",
      "Epoch 7/10\n",
      "12/50 [======>.......................] - ETA: 0s - loss: 0.5474"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/ebanner/.anaconda/envs/py27/lib/python2.7/site-packages/keras/callbacks.py:67: UserWarning: Method on_batch_end() is slow compared to the batch update (0.351961). Check your callbacks.\n",
      "  % delta_t_median)\n",
      "/home/ebanner/.anaconda/envs/py27/lib/python2.7/site-packages/keras/callbacks.py:67: UserWarning: Method on_batch_end() is slow compared to the batch update (0.345528). Check your callbacks.\n",
      "  % delta_t_median)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "gender accuracy: 0.98\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "36/50 [====================>.........] - ETA: 0s - loss: 0.5665\n",
      "gender accuracy: 0.98\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "50/50 [==============================] - 3s - loss: 0.5994 - val_loss: 0.3274\n",
      "Epoch 00006: saving model to weights.hdf5\n",
      "Epoch 8/10\n",
      " 6/50 [==>...........................] - ETA: 0s - loss: 0.1426\n",
      "gender accuracy: 0.98\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "12/50 [======>.......................] - ETA: 2s - loss: 0.2264"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/ebanner/.anaconda/envs/py27/lib/python2.7/site-packages/keras/callbacks.py:67: UserWarning: Method on_batch_end() is slow compared to the batch update (0.705337). Check your callbacks.\n",
      "  % delta_t_median)\n",
      "/home/ebanner/.anaconda/envs/py27/lib/python2.7/site-packages/keras/callbacks.py:67: UserWarning: Method on_batch_end() is slow compared to the batch update (0.352977). Check your callbacks.\n",
      "  % delta_t_median)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "30/50 [=================>............] - ETA: 0s - loss: 0.4041\n",
      "gender accuracy: 0.98\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "48/50 [===========================>..] - ETA: 0s - loss: 0.4906\n",
      "gender accuracy: 0.98\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "50/50 [==============================] - 3s - loss: 0.4746 - val_loss: 0.3199\n",
      "Epoch 00007: saving model to weights.hdf5\n",
      "Epoch 9/10\n",
      "24/50 [=============>................] - ETA: 0s - loss: 0.4347\n",
      "gender accuracy: 0.98\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "48/50 [===========================>..] - ETA: 0s - loss: 0.5871\n",
      "gender accuracy: 0.98\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "50/50 [==============================] - 3s - loss: 0.5678 - val_loss: 0.3168\n",
      "Epoch 00008: saving model to weights.hdf5\n",
      "Epoch 10/10\n",
      "18/50 [=========>....................] - ETA: 0s - loss: 0.6300\n",
      "gender accuracy: 0.98\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "42/50 [========================>.....] - ETA: 0s - loss: 0.4996\n",
      "gender accuracy: 0.98\n",
      "ec_safety_study accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n",
      "50/50 [==============================] - 3s - loss: 0.5125 - val_loss: 0.2992\n",
      "Epoch 00009: saving model to weights.hdf5\n"
     ]
    }
   ],
   "source": [
    "batch_size = 6\n",
    "num_epochs = 10\n",
    "\n",
    "callback = AccuracyCallback(data, val_dict, batch_size, num_train=len(abstracts_padded), val_every=2)\n",
    "checkpointer = keras.callbacks.ModelCheckpoint(filepath=\"weights.hdf5\", verbose=1)\n",
    "\n",
    "history = model.fit(data, validation_data=data, batch_size=batch_size, callbacks=[callback, checkpointer], nb_epoch=10)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Confusion Matrix"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAMcAAAJpCAYAAAAZjCZxAAAABHNCSVQICAgIfAhkiAAAAAlwSFlz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\nwyzD4TDLcDjMMhwOswyHwyzj/wMx8/RbWZIa4QAAAABJRU5ErkJggg==\n",
      "text/plain": [
       "<matplotlib.figure.Figure at 0x7f54c5b9ccd0>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from sklearn.metrics import confusion_matrix\n",
    "from support import plot_confusion_matrix\n",
    "\n",
    "X_val = abstracts_padded\n",
    "\n",
    "predictions = model.predict({'input': X_val})\n",
    "\n",
    "fig = plt.figure(figsize=(10,10))\n",
    "plt.clf()\n",
    "\n",
    "for i, label in enumerate(labels, start=1):\n",
    "    axes = fig.add_subplot(len(labels), 1, i)\n",
    "    \n",
    "    y_row, y_pred = val_dict[label], predictions[label]\n",
    "    \n",
    "    cm = confusion_matrix(y_row, y_pred.argmax(axis=1))\n",
    "    plot_confusion_matrix(cm, class_names[label])\n",
    "    \n",
    "    fig.subplots_adjust(wspace=.35, hspace=.65)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Examine Bigrams Which Filters Fire on"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {
    "collapsed": false,
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "D-Cycloserine, a partial agonist at the glycine site of the N-methyl-D-aspartate receptor, has demonstrated inconsistent efficacy for negative and cognitive symptoms of schizophrenia. The strongest evidence for efficacy has come from studies using D-cycloserine at a dose of 50 mg/day added to conventional antipsychotics in trials of 8 weeks duration or less. \n",
      "                 To assess the efficacy for negative symptoms and cognitive impairment of D-cycloserine augmentation of conventional antipsychotics in a 6-month trial. \n",
      "                 Fifty-five schizophrenia patients with prominent negative symptoms, treated with conventional antipsychotics, were randomly assigned to treatment with D-cycloserine 50 mg/day or placebo for 6 months in a double-blind, parallel group design. \n",
      "                 Twenty-six subjects completed the 6-month trial; drop-out rates did not differ between treatment groups. D-Cycloserine treatment did not differ from placebo treatment on any primary outcome measure at 8 or 24 weeks, including response of negative symptoms and performance on a cognitive battery. Serum D-cycloserine concentrations did not correlate with response of negative symptoms. \n",
      "                 D-Cycloserine did not exhibit therapeutic effects in this trial, possibly reflecting the high drop-out rate, a narrow range of therapeutic serum concentrations, a modest magnitude of therapeutic effect for the selected outcome measures, or loss of efficacy over time. Because D-cycloserine is a partial agonist with relatively low affinity for the glycine site, the magnitude of potential therapeutic effect may be smaller than that achieved by the higher-affinity full agonists, glycine and D-serine.\n",
      "\n",
      "ec_safety_study False\n",
      "gender Both\n",
      "phase_2 False\n",
      "\n",
      "0.483882170357 6 months\n",
      "0.442097513715 months in\n",
      "0.401171590589 for 6\n",
      "0.399039688733 weeks duration\n",
      "0.388805528366 at 8\n",
      "0.381508896673 of 8\n",
      "0.359971558566 8 weeks\n",
      "0.349851899324 24 weeks\n",
      "0.255738436058 or 24\n",
      "0.255582883778 weeks ,\n",
      "\n",
      "0.822417727552 double-blind ,\n",
      "0.752816166688 trial .\n",
      "0.741393114117 trial ,\n",
      "0.72533473975 trial ;\n",
      "0.604135196638 design .\n",
      "0.476927632317 schizophrenia .\n",
      "0.423094712404 trials of\n",
      "0.406081868632 parallel group\n",
      "0.404825669869 measures ,\n",
      "0.376969567218 rate ,\n",
      "\n",
      "0.324283209529 6 months\n",
      "0.320321479488 of 8\n",
      "0.218370638859 has come\n",
      "0.217957232461 come from\n",
      "0.212038598616 8 weeks\n",
      "0.206576172865 or 24\n",
      "0.20430589081 24 weeks\n",
      "0.200070909406 at 8\n",
      "0.199639563179 over time\n",
      "0.189068702263 subjects completed\n",
      "\n",
      "0.141214687578 N-methyl-D-aspartate receptor\n",
      "0.0973308675196 <MASK> D-Cycloserine\n",
      "0.0927423801157 higher-affinity full\n",
      "0.0454002030493 come from\n",
      "0.0320040450965 differ from\n",
      "0.031981407201 . Serum\n",
      "0.0179931330701 receptor ,\n",
      "0.0166840682365 were randomly\n",
      "0.015742799117 partial agonist\n",
      "0.015742799117 partial agonist\n",
      "\n",
      "0.867068162365 the selected\n",
      "0.699056578397 measure at\n",
      "0.629254341748 randomly assigned\n",
      "0.570328490245 primary outcome\n",
      "0.5053478919 selected outcome\n",
      "0.432453053083 to treatment\n",
      "0.362741269783 The strongest\n",
      "0.332264307485 magnitude of\n",
      "0.332264307485 magnitude of\n",
      "0.312728923862 to conventional\n",
      "\n",
      "0.486482296649 using D-cycloserine\n",
      "0.331198902995 studies using\n",
      "0.233768964963 selected outcome\n",
      "0.211542019568 demonstrated inconsistent\n",
      "0.176386692385 design .\n",
      "0.127232309914 that achieved\n",
      "0.126526298898 a cognitive\n",
      "0.126363791172 by the\n",
      "0.123192795035 a 6-month\n",
      "0.103014985623 primary outcome\n",
      "\n",
      "0.306451437466 and D-serine\n",
      "0.241919149254 and performance\n",
      "0.227393857109 . D-Cycloserine\n",
      "0.227393857109 . D-Cycloserine\n",
      "0.20144566216 in trials\n",
      "0.187145714524 cognitive battery\n",
      "0.183826221051 including response\n",
      "0.182691098874 using D-cycloserine\n",
      "0.173099136167 for efficacy\n",
      "0.164911087306 subjects completed\n",
      "\n",
      "0.496569213145 affinity for\n",
      "0.36828406925 effect for\n",
      "0.355725659206 low affinity\n",
      "0.340575806224 response of\n",
      "0.340575806224 response of\n",
      "0.274347635225 efficacy for\n",
      "0.274347635225 efficacy for\n",
      "0.265790886856 evidence for\n",
      "0.247117535266 glycine and\n",
      "0.214630849397 exhibit therapeutic\n",
      "\n",
      "0.617500624366 is a\n",
      "0.595695857195 in a\n",
      "0.595695857195 in a\n",
      "0.587607191087 for the\n",
      "0.587607191087 for the\n",
      "0.584213652925 assess the\n",
      "0.560415955443 , a\n",
      "0.560415955443 , a\n",
      "0.560415955443 , a\n",
      "0.512987193864 therapeutic effect\n",
      "\n",
      "0.336136190859 Serum D-cycloserine\n",
      "0.294420434628 serum concentrations\n",
      "0.244047950487 N-methyl-D-aspartate receptor\n",
      "0.130368887361 the glycine\n",
      "0.130368887361 the glycine\n",
      "0.124945652355 glycine site\n",
      "0.124945652355 glycine site\n",
      "0.119874435817 therapeutic serum\n",
      "0.105546355287 D-cycloserine concentrations\n",
      "0.049151062771 , glycine\n",
      "\n",
      "0.424025627621 primary outcome\n",
      "0.394615294919 selected outcome\n",
      "0.363809932029 correlate with\n",
      "0.348197704715 measure at\n",
      "0.308097055141 trial .\n",
      "0.253309302786 parallel group\n",
      "0.226322374495 trial ;\n",
      "0.224700150375 trials of\n",
      "0.203867467204 patients with\n",
      "0.187515542804 agonist with\n",
      "\n",
      "0.0987234832878 therapeutic serum\n",
      "0.0794269266264 a cognitive\n",
      "0.0677588825832 D-serine .\n",
      "0.0564824525163 agonist at\n",
      "0.0427206000419 D-Cycloserine treatment\n",
      "0.0305240899954 cognitive battery\n",
      "0.0286683205763 augmentation of\n",
      "0.0271777644425 therapeutic effects\n",
      "0.0232316074226 D-cycloserine augmentation\n",
      "0.0149442380245 subjects completed\n",
      "\n",
      "0.23340101615 potential therapeutic\n",
      "0.174910158509 for efficacy\n",
      "0.159497341685 exhibit therapeutic\n",
      "0.135136551328 therapeutic effects\n",
      "0.124910953533 partial agonist\n",
      "0.124910953533 partial agonist\n",
      "0.119129554648 the efficacy\n",
      "0.107458949921 full agonists\n",
      "0.0911248369272 strongest evidence\n",
      "0.089785508932 of therapeutic\n",
      "\n",
      "0.382705145617 drop-out rates\n",
      "0.375397877941 drop-out rate\n",
      "0.295160643875 D-cycloserine concentrations\n",
      "0.26901624366 D-cycloserine 50\n",
      "0.236670083455 placebo treatment\n",
      "0.234173148279 N-methyl-D-aspartate receptor\n",
      "0.187491651861 D-cycloserine at\n",
      "0.180850155946 D-cycloserine augmentation\n",
      "0.176136329905 subjects completed\n",
      "0.162356003445 modest magnitude\n",
      "\n",
      "0.277812907003 and D-serine\n",
      "0.262110796903 a partial\n",
      "0.262110796903 a partial\n",
      "0.26039448747 a 6-month\n",
      "0.256324182495 a dose\n",
      "0.253542326999 and performance\n",
      "0.233617330714 a double-blind\n",
      "0.198538067473 a modest\n",
      "0.194956018466 a cognitive\n",
      "0.176150991152 . To\n",
      "\n",
      "0.380030718847 augmentation of\n",
      "0.37707479547 response of\n",
      "0.37707479547 response of\n",
      "0.363190935758 magnitude of\n",
      "0.363190935758 magnitude of\n",
      "0.333846741079 impairment of\n",
      "0.302801266032 symptoms of\n",
      "0.302527160729 dose of\n",
      "0.264336857898 schizophrenia patients\n",
      "0.260400154363 trials of\n",
      "\n",
      "0.503582328834 with prominent\n",
      "0.472598881096 with response\n",
      "0.462388313307 with conventional\n",
      "0.409348883635 with relatively\n",
      "0.376200077874 with D-cycloserine\n",
      "0.374331892612 duration or\n",
      "0.370696490929 has demonstrated\n",
      "0.34520491512 or less\n",
      "0.312318739986 efficacy for\n",
      "0.312318739986 efficacy for\n",
      "\n",
      "0.641603277007 double-blind ,\n",
      "0.533574851685 trial ,\n",
      "0.363922637409 trial ;\n",
      "0.269018603434 antipsychotics ,\n",
      "0.266341412297 trial .\n",
      "0.261580251042 symptoms ,\n",
      "0.245560943234 trials of\n",
      "0.238047622639 or less\n",
      "0.236914782204 agonists ,\n",
      "0.229080046503 weeks ,\n",
      "\n",
      "0.823431024643 mg/day or\n",
      "0.595193102118 duration or\n",
      "0.579190817097 , or\n",
      "0.508760953927 8 or\n",
      "0.498418109675 placebo treatment\n",
      "0.401182594597 D-cycloserine 50\n",
      "0.388311187708 D-cycloserine augmentation\n",
      "0.355135565283 mg/day added\n",
      "0.346388046393 placebo for\n",
      "0.311826333063 parallel group\n",
      "\n",
      "0.443348444022 8 weeks\n",
      "0.329503834474 24 weeks\n",
      "0.272728306098 6 months\n",
      "0.244213138043 8 or\n",
      "0.127799251968 prominent negative\n",
      "0.0721157408556 at 8\n",
      "0.0709184905586 glycine site\n",
      "0.0709184905586 glycine site\n",
      "0.0708609124851 selected outcome\n",
      "0.0704308493835 50 mg/day\n",
      "\n",
      "Patients with metastatic or recurrent Ewing's sarcoma family of tumors and alveolar rhabdomyosarcoma have <25% 5-year survival in most studies. This study administered a novel immunotherapy regimen aimed at consolidating remission in these patients. \n",
      "                 Fifty-two patients with translocation positive, recurrent, or metastatic Ewing's sarcoma family of tumors or alveolar rhabdomyosarcoma underwent prechemotherapy cell harvest via apheresis for potential receipt of immunotherapy. Following completion of standard multimodal therapy, 30 patients ultimately initiated immunotherapy and were sequentially assigned to three cohorts. All cohorts received autologous T cells, influenza vaccinations, and dendritic cells pulsed with peptides derived from tumor-specific translocation breakpoints and E7, a peptide known to bind HLA-A2. Cohort 1 received moderate-dose recombinant human interleukin-2 (rhIL-2), cohort 2 received low-dose rhIL-2, and cohort 3 did not receive rhIL-2. \n",
      "                 All immunotherapy recipients generated influenza-specific immune responses, whereas immune responses to the translocation breakpoint peptides occurred in 39%, and only 25% of HLA-A2(+) patients developed E7-specific responses. Toxicity was minimal. Intention-to-treat analysis revealed a 31% 5-year overall survival for all patients apheresed (median potential follow-up 7.3 years) with a 43% 5-year overall survival for patients initiating immunotherapy. \n",
      "                 Consolidative immunotherapy is a scientifically based and clinically practical approach for integrating immunotherapy into a multimodal regimen for chemoresponsive cancer. Patients receiving immunotherapy experienced minimal toxicity and favorable survival. The robust influenza immune responses observed suggest that postchemotherapy immune incompetence will not fundamentally limit this approach. Future studies will seek to increase efficacy by using more immunogenic antigens and more potent dendritic cells.\n",
      "\n",
      "ec_safety_study True\n",
      "gender Both\n",
      "phase_2 True\n",
      "\n",
      "0.870852773404 follow-up 7.3\n",
      "0.499129940758 % of\n",
      "0.498736080959 % 5-year\n",
      "0.498736080959 % 5-year\n",
      "0.498736080959 % 5-year\n",
      "0.480145638864 % ,\n",
      "0.423267539887 cohort 3\n",
      "0.395559060026 years )\n",
      "0.353795079909 cohort 2\n",
      "0.296601092862 ( median\n",
      "\n",
      "0.497277190761 interleukin-2 (\n",
      "0.468311081378 HLA-A2 (\n",
      "0.464450618661 studies .\n",
      "0.435984836309 HLA-A2 .\n",
      "0.385847829857 apheresed (\n",
      "0.377877805027 E7 ,\n",
      "0.372419276589 therapy ,\n",
      "0.360536883586 positive ,\n",
      "0.352696911626 responses .\n",
      "0.352457955974 approach .\n",
      "\n",
      "0.376608354886 7.3 years\n",
      "0.222783760037 of standard\n",
      "0.188503966243 Following completion\n",
      "0.182337555566 ultimately initiated\n",
      "0.174781811604 of immunotherapy\n",
      "0.15853116175 a 31\n",
      "0.149875184563 's sarcoma\n",
      "0.149875184563 's sarcoma\n",
      "0.148093323662 of HLA-A2\n",
      "0.141262375457 potential follow-up\n",
      "\n",
      "0.476986794316 cells pulsed\n",
      "0.346758697716 potent dendritic\n",
      "0.317019875408 human interleukin-2\n",
      "0.308653622766 cells ,\n",
      "0.288654086625 via apheresis\n",
      "0.261715539411 cells .\n",
      "0.208558790256 receive rhIL-2\n",
      "0.190376102243 dendritic cells\n",
      "0.190376102243 dendritic cells\n",
      "0.184084518452 cell harvest\n",
      "\n",
      "0.696347138879 sequentially assigned\n",
      "0.596485144165 to three\n",
      "0.416730251155 to bind\n",
      "0.416196741376 scientifically based\n",
      "0.350199734695 will seek\n",
      "0.306975180305 not receive\n",
      "0.290745298699 to the\n",
      "0.280690019216 . Fifty-two\n",
      "0.278588381259 and favorable\n",
      "0.261140973867 a scientifically\n",
      "\n",
      "0.903071264335 analysis revealed\n",
      "0.570862089928 developed E7-specific\n",
      "0.51389106195 using more\n",
      "0.43857686688 Intention-to-treat analysis\n",
      "0.369954564808 approach .\n",
      "0.355759748726 generated influenza-specific\n",
      "0.337734046763 robust influenza\n",
      "0.316807069604 revealed a\n",
      "0.307590493544 based and\n",
      "0.294741461091 approach for\n",
      "\n",
      "0.922740963317 ( rhIL-2\n",
      "0.71453234955 low-dose rhIL-2\n",
      "0.696038879889 received autologous\n",
      "0.679870666883 receive rhIL-2\n",
      "0.564922277857 from tumor-specific\n",
      "0.557073978791 and dendritic\n",
      "0.550587392413 human interleukin-2\n",
      "0.537977313247 initiated immunotherapy\n",
      "0.534953489316 initiating immunotherapy\n",
      "0.526142436261 receiving immunotherapy\n",
      "\n",
      "0.427434832279 regimen for\n",
      "0.407708575382 peptides derived\n",
      "0.363211516345 approach for\n",
      "0.347165988923 survival for\n",
      "0.347165988923 survival for\n",
      "0.339609602342 apheresis for\n",
      "0.317913966561 peptide known\n",
      "0.29745297211 tumors and\n",
      "0.296497692089 antigens and\n",
      "0.293320468388 responses .\n",
      "\n",
      "0.617500624366 is a\n",
      "0.595515990048 with a\n",
      "0.560415955443 , a\n",
      "0.52744667465 to the\n",
      "0.478270666081 administered a\n",
      "0.476381977192 into a\n",
      "0.450409498911 revealed a\n",
      "0.424572938015 practical approach\n",
      "0.389646098678 efficacy by\n",
      "0.359892046919 clinically practical\n",
      "\n",
      "0.212607835612 immune incompetence\n",
      "0.176748855023 immunogenic antigens\n",
      "0.154692329037 breakpoint peptides\n",
      "0.123653157097 bind HLA-A2\n",
      "0.114188580785 human interleukin-2\n",
      "0.110791941414 peptide known\n",
      "0.0944982776378 influenza-specific immune\n",
      "0.0916881656986 peptides occurred\n",
      "0.0753989250403 antigens and\n",
      "0.0685175274569 HLA-A2 (\n",
      "\n",
      "0.219096834311 study administered\n",
      "0.214879300096 Patients with\n",
      "0.203867467204 patients with\n",
      "0.189985117309 pulsed with\n",
      "0.182289860093 overall survival\n",
      "0.182289860093 overall survival\n",
      "0.176651345934 ) with\n",
      "0.160968891832 cohort 3\n",
      "0.159015086296 increase efficacy\n",
      "0.14464211919 studies will\n",
      "\n",
      "0.834142956851 cancer .\n",
      "0.445198902797 chemoresponsive cancer\n",
      "0.309887484177 metastatic Ewing\n",
      "0.207112943015 metastatic or\n",
      "0.194546846458 potential receipt\n",
      "0.181171458627 recombinant human\n",
      "0.160823826205 human interleukin-2\n",
      "0.130578006089 immune incompetence\n",
      "0.119405913431 tumors and\n",
      "0.108988637974 with metastatic\n",
      "\n",
      "0.340619279348 novel immunotherapy\n",
      "0.338980162769 integrating immunotherapy\n",
      "0.323966654286 ( rhIL-2\n",
      "0.317694996965 autologous T\n",
      "0.280912375145 human interleukin-2\n",
      "0.261020910687 Consolidative immunotherapy\n",
      "0.259975309886 low-dose rhIL-2\n",
      "0.229525347824 receive rhIL-2\n",
      "0.226757119614 immunotherapy recipients\n",
      "0.221154226683 Future studies\n",
      "\n",
      "0.232868508531 Cohort 1\n",
      "0.226874388892 cohort 2\n",
      "0.197011411078 patients ultimately\n",
      "0.166134406093 Intention-to-treat analysis\n",
      "0.163137598002 5-year overall\n",
      "0.163137598002 5-year overall\n",
      "0.158374396105 moderate-dose recombinant\n",
      "0.144771897231 cohort 3\n",
      "0.144344374292 bind HLA-A2\n",
      "0.141201428265 5-year survival\n",
      "\n",
      "0.502027461789 alveolar rhabdomyosarcoma\n",
      "0.502027461789 alveolar rhabdomyosarcoma\n",
      "0.454480375202 of tumors\n",
      "0.454480375202 of tumors\n",
      "0.453973149021 's sarcoma\n",
      "0.453973149021 's sarcoma\n",
      "0.423664362128 or metastatic\n",
      "0.377695575134 metastatic Ewing\n",
      "0.363423304653 recurrent Ewing\n",
      "0.320215137905 integrating immunotherapy\n",
      "\n",
      "0.327792759725 regimen aimed\n",
      "0.311096369558 regimen for\n",
      "0.28619556525 immunogenic antigens\n",
      "0.278216749243 completion of\n",
      "0.265507687974 receipt of\n",
      "0.255873660237 immunotherapy experienced\n",
      "0.254309121768 remission in\n",
      "0.232014554832 moderate-dose recombinant\n",
      "0.231791758509 dendritic cells\n",
      "0.231791758509 dendritic cells\n",
      "\n",
      "0.571007456151 have <\n",
      "0.516163421164 rhIL-2 )\n",
      "0.513744432747 years )\n",
      "0.49809991467 + )\n",
      "0.490181257814 with metastatic\n",
      "0.456971641816 with peptides\n",
      "0.445442341947 with translocation\n",
      "0.439882854296 43 %\n",
      "0.435286409748 39 %\n",
      "0.412629503061 31 %\n",
      "\n",
      "0.329338190259 immunotherapy and\n",
      "0.322026609725 vaccinations ,\n",
      "0.307190564226 E7 ,\n",
      "0.286181755546 efficacy by\n",
      "0.277941185237 recurrent ,\n",
      "0.263707152658 cells ,\n",
      "0.249829382989 Future studies\n",
      "0.243723387091 rhIL-2 ,\n",
      "0.243650866907 therapy ,\n",
      "0.229278849099 immunotherapy experienced\n",
      "\n",
      "0.579190817097 , or\n",
      "0.35171161631 tumors or\n",
      "0.281039145463 metastatic or\n",
      "0.271368518908 peptides occurred\n",
      "0.271121921786 efficacy by\n",
      "0.255194590836 responses to\n",
      "0.253317289664 sequentially assigned\n",
      "0.252554868303 assigned to\n",
      "0.229348039892 peptide known\n",
      "0.223504128828 a peptide\n",
      "\n",
      "0.433002225658 tumor-specific translocation\n",
      "0.341252369523 translocation breakpoint\n",
      "0.310730356746 translocation breakpoints\n",
      "0.294855719125 T cells\n",
      "0.284649876876 breakpoint peptides\n",
      "0.241796978006 breakpoints and\n",
      "0.238842939288 translocation positive\n",
      "0.210096829174 alveolar rhabdomyosarcoma\n",
      "0.210096829174 alveolar rhabdomyosarcoma\n",
      "0.200650384753 Ewing 's\n",
      "\n",
      "To determine the maximum tolerated dose (MTD) of weekly paclitaxel and cisplatin chemotherapy concurrent with extended field irradiation in women with cervical cancer metastatic to the para-aortic nodes. \n",
      "                 Patients with carcinoma of the cervix and histologically documented para-aortic node metastases were eligible for this phase I/II trial. Chemotherapy agents were administered weekly concurrent with extended field radiation with escalating doses of paclitaxel from 30-50 mg/m(2) in each of three cohorts of three patients each. A phase II cohort was then evaluated at the selected maximum tolerated dose (MTD). \n",
      "                 The MTD was determined to be cisplatin 40 mg/m(2) (maximum dose of 70 mg) and paclitaxel 40 mg/m(2) administered weekly for six cycles concurrent with extended field radiation therapy. There were 19 evaluable patients for the phase II analysis of toxicity and efficacy. Grade three and four gastrointestinal toxicity was seen in 6 and neutropenia in 7. Radiation therapy was successfully completed in 36.8% of patients at eight weeks and in 68.4% of patients at nine weeks, with a median time to completion was 56 days. A total of 27 evaluable patients were enrolled, twelve are dead (mean survival of those deceased is 25 months), and 15 (56%) are alive, and have been followed for a mean of 48 months (range 25-68; median of 46 months). \n",
      "                 Paclitaxel and cisplatin combination chemotherapy concurrent with extended field pelvic para-aortic irradiation can be administered at the described MTD and shows a higher than previously reported disease-free survival in relation to historical data. The 56% survival to date, and 50% estimated 48 month survival, warrants validation in a larger prospective cohort. Central radiation dose reduction is being considered in the next trial to decrease late toxicity of regimen.\n",
      "\n",
      "ec_safety_study False\n",
      "gender Female\n",
      "phase_2 False\n",
      "\n",
      "0.584239032961 % estimated\n",
      "0.578847223654 46 months\n",
      "0.522643798272 % )\n",
      "0.510307537867 % survival\n",
      "0.499129940758 % of\n",
      "0.499129940758 % of\n",
      "0.463678908092 48 months\n",
      "0.460318601505 months )\n",
      "0.460318601505 months )\n",
      "0.443358518928 in 6\n",
      "\n",
      "0.752816166688 trial .\n",
      "0.479679673655 trial to\n",
      "0.459703483914 efficacy .\n",
      "0.416707047468 enrolled ,\n",
      "0.401936125571 2 )\n",
      "0.401936125571 2 )\n",
      "0.401936125571 2 )\n",
      "0.38420700588 three and\n",
      "0.38384232916 therapy .\n",
      "0.380352955813 each .\n",
      "\n",
      "0.325552705832 25 months\n",
      "0.307973025266 of 27\n",
      "0.307428545703 of 48\n",
      "0.299820203577 of 46\n",
      "0.290051411291 48 months\n",
      "0.258376712489 48 month\n",
      "0.251302709746 46 months\n",
      "0.202657115972 to completion\n",
      "0.194445084206 of 70\n",
      "0.193351597602 range 25-68\n",
      "\n",
      "0.111514319195 cisplatin chemotherapy\n",
      "0.0924416627989 were administered\n",
      "0.0803755733538 six cycles\n",
      "0.0581426257503 Radiation therapy\n",
      "0.0471711101863 cancer metastatic\n",
      "0.0463486981273 are dead\n",
      "0.0425876954154 be cisplatin\n",
      "0.0251309123963 30-50 mg/m\n",
      "0.0224790316811 be administered\n",
      "0.0211293057077 cervical cancer\n",
      "\n",
      "0.867068162365 the selected\n",
      "0.487756086467 to date\n",
      "0.468859976223 to be\n",
      "0.459730483265 to historical\n",
      "0.436328672214 maximum tolerated\n",
      "0.436328672214 maximum tolerated\n",
      "0.366933148525 maximum dose\n",
      "0.360873490467 to completion\n",
      "0.360348080503 then evaluated\n",
      "0.329913102806 and four\n",
      "\n",
      "0.766140375612 analysis of\n",
      "0.321576512286 successfully completed\n",
      "0.305322042574 determined to\n",
      "0.272549643243 estimated 48\n",
      "0.259959496415 validation in\n",
      "0.227185957281 data .\n",
      "0.215002965423 then evaluated\n",
      "0.205411370353 was then\n",
      "0.195559500884 three patients\n",
      "0.182815515001 described MTD\n",
      "\n",
      "0.714933349174 and paclitaxel\n",
      "0.708798228452 ) administered\n",
      "0.652466261831 and cisplatin\n",
      "0.652466261831 and cisplatin\n",
      "0.603626108077 . Paclitaxel\n",
      "0.577403095724 weekly paclitaxel\n",
      "0.561664283351 of paclitaxel\n",
      "0.492976163372 . Chemotherapy\n",
      "0.482950886611 ( MTD\n",
      "0.482950886611 ( MTD\n",
      "\n",
      "0.30274915641 weekly for\n",
      "0.247324858537 patients for\n",
      "0.246999630263 eligible for\n",
      "0.190037726602 MTD and\n",
      "0.182528009254 followed for\n",
      "0.168173429503 metastases were\n",
      "0.168125752296 doses of\n",
      "0.1622189986 toxicity and\n",
      "0.150381672867 at the\n",
      "0.150381672867 at the\n",
      "\n",
      "0.658130987739 for a\n",
      "0.601650103085 shows a\n",
      "0.595695857195 in a\n",
      "0.595515990048 with a\n",
      "0.587607191087 for the\n",
      "0.533140849727 determine the\n",
      "0.52744667465 to the\n",
      "0.525172060542 in the\n",
      "0.498433417011 of the\n",
      "0.490221595007 efficacy .\n",
      "\n",
      "0.116775924415 para-aortic node\n",
      "0.112729460709 para-aortic nodes\n",
      "0.0883349907236 cervical cancer\n",
      "0.0325430909667 histologically documented\n",
      "0.0274708147227 four gastrointestinal\n",
      "0.0267938481525 the cervix\n",
      "0.0245766132152 range 25-68\n",
      "0.00952240793556 node metastases\n",
      "0.0 <MASK> <MASK>\n",
      "0.0 <MASK> <MASK>\n",
      "\n",
      "0.353157163921 trial to\n",
      "0.3429449679 prospective cohort\n",
      "0.308097055141 trial .\n",
      "0.245653220697 concurrent with\n",
      "0.245653220697 concurrent with\n",
      "0.245653220697 concurrent with\n",
      "0.245653220697 concurrent with\n",
      "0.223861772948 cohort was\n",
      "0.214879300096 Patients with\n",
      "0.16608680993 , with\n",
      "\n",
      "1.10533105036 cancer metastatic\n",
      "0.67192826912 with cervical\n",
      "0.665575494826 the cervix\n",
      "0.47614915114 in women\n",
      "0.475427232993 field pelvic\n",
      "0.421559814819 cervical cancer\n",
      "0.308821358144 metastatic to\n",
      "0.279881511178 carcinoma of\n",
      "0.249940334432 para-aortic node\n",
      "0.240000971659 field radiation\n",
      "\n",
      "0.32940568694 gastrointestinal toxicity\n",
      "0.208827323488 ( MTD\n",
      "0.208827323488 ( MTD\n",
      "0.201783729643 late toxicity\n",
      "0.200422901225 of toxicity\n",
      "0.196123219942 and neutropenia\n",
      "0.188350710908 described MTD\n",
      "0.168728171173 cancer metastatic\n",
      "0.158612078359 warrants validation\n",
      "0.15410386137 The MTD\n",
      "\n",
      "0.573679851982 phase II\n",
      "0.573679851982 phase II\n",
      "0.319843177846 phase I/II\n",
      "0.282056176217 trial to\n",
      "0.186038713267 decrease late\n",
      "0.182529544861 . Grade\n",
      "0.166838960569 late toxicity\n",
      "0.127702029206 patients were\n",
      "0.126402432971 metastatic to\n",
      "0.123771024772 this phase\n",
      "\n",
      "0.418322996239 with carcinoma\n",
      "0.3851725515 . Chemotherapy\n",
      "0.361076693841 and histologically\n",
      "0.35800713293 and cisplatin\n",
      "0.35800713293 and cisplatin\n",
      "0.328053520461 and neutropenia\n",
      "0.317168224627 and paclitaxel\n",
      "0.306394728696 node metastases\n",
      "0.273110451377 a median\n",
      "0.26642837396 . Grade\n",
      "\n",
      "0.318620442451 doses of\n",
      "0.316217432585 cohorts of\n",
      "0.314954921298 weekly for\n",
      "0.314562001357 weekly paclitaxel\n",
      "0.312356634392 weekly concurrent\n",
      "0.302527160729 dose of\n",
      "0.294945340228 paclitaxel from\n",
      "0.278561301347 cisplatin 40\n",
      "0.27811640127 regimen .\n",
      "0.265949033675 each of\n",
      "\n",
      "0.618060118229 MTD )\n",
      "0.618060118229 MTD )\n",
      "0.591344205798 was 56\n",
      "0.521519240967 with carcinoma\n",
      "0.519946175385 % )\n",
      "0.501943513796 months )\n",
      "0.501943513796 months )\n",
      "0.496421281898 with cervical\n",
      "0.49625427032 dose (\n",
      "0.49625427032 dose (\n",
      "\n",
      "0.435118656489 enrolled ,\n",
      "0.362173594314 date ,\n",
      "0.316913198274 prospective cohort\n",
      "0.266341412297 trial .\n",
      "0.247024334632 alive ,\n",
      "0.229080046503 weeks ,\n",
      "0.206024739656 efficacy .\n",
      "0.187584925162 trial to\n",
      "0.167848876867 cohort .\n",
      "0.165347465534 ) ,\n",
      "\n",
      "0.390166598574 date ,\n",
      "0.335077127573 been followed\n",
      "0.298569600838 weekly concurrent\n",
      "0.293055080149 trial to\n",
      "0.292049201188 efficacy .\n",
      "0.284949672147 combination chemotherapy\n",
      "0.278415782734 cisplatin combination\n",
      "0.266890772785 mg )\n",
      "0.239624619309 weekly paclitaxel\n",
      "0.239342067325 dose reduction\n",
      "\n",
      "0.364806751677 56 days\n",
      "0.352697684545 48 month\n",
      "0.27001149824 nine weeks\n",
      "0.264966677591 eight weeks\n",
      "0.248014436909 19 evaluable\n",
      "0.207195144635 six cycles\n",
      "0.18731657448 40 mg/m\n",
      "0.18731657448 40 mg/m\n",
      "0.18285706504 27 evaluable\n",
      "0.168963313829 25 months\n",
      "\n",
      "While primary cisplatin-based intraperitoneal chemotherapy has been shown to favorably impact survival in small-volume residual advanced ovarian cancer, there is a need to develop strategies that improve the effectiveness of this approach. \n",
      "                 A multi-center phase 2 trial was conducted that added intravenous pegylated liposomal doxorubicin (day 8; 30-40 mg/m(2)) to a regimen of intraperitoneal cisplatin (day 2; 75 mg/m(2)) and intravenous (day 1; 135 mg/m(2)) plus intraperitoneal (day 8; 60 mg/m(2)) paclitaxel. Treatment was initially delivered on an every 3-week schedule, but was modified to an every 4-week program due to excessive toxicity. Patients were to receive 6 cycles of this regimen. \n",
      "                 Of 68 patients entering this trial, 63 patients were eligible and evaluable, of whom 39 (62%) completed 6 cycles. Overall, 32 (51%) experienced at least 1 grade 4 or worse toxicity (most commonly hematologic) including 5 treatment-related deaths. Median progression-free survival (PFS) was 25 months (2-year PFS: 52%) and median overall survival 51 months, an outcome similar to previous reports of cisplatin-based intraperitoneal chemotherapy in comparable patient populations. Seventeen patients (27% of all eligible patients) were without evidence of disease recurrence >4 years following entry into the trial. \n",
      "                 Both the overall trial outcome, and specifically the excessively severe systemic toxicity of this regimen would prevent its future development in this exact form. The provocative PFS in a subset of individuals should encourage the development of alternative strategies designed to optimize the delivery of regional therapy in ovarian cancer management.\n",
      "\n",
      "ec_safety_study False\n",
      "gender Female\n",
      "phase_2 True\n",
      "\n",
      "0.580578221519 51 months\n",
      "0.569720720806 completed 6\n",
      "0.522643798272 % )\n",
      "0.522643798272 % )\n",
      "0.522643798272 % )\n",
      "0.519829503238 receive 6\n",
      "0.510495531607 grade 4\n",
      "0.499129940758 % of\n",
      "0.456120316864 day 8\n",
      "0.456120316864 day 8\n",
      "\n",
      "0.752816166688 trial .\n",
      "0.741393114117 trial ,\n",
      "0.48791071937 form .\n",
      "0.45960282513 trial was\n",
      "0.434784675697 multi-center phase\n",
      "0.434430267293 trial outcome\n",
      "0.42392568961 2 ;\n",
      "0.403950555774 outcome ,\n",
      "0.401936125571 2 )\n",
      "0.401936125571 2 )\n",
      "\n",
      "0.372021966089 4 years\n",
      "0.325552705832 25 months\n",
      "0.254968742794 51 months\n",
      "0.251756254781 of cisplatin-based\n",
      "0.210538296654 completed 6\n",
      "0.192138808868 day 8\n",
      "0.192138808868 day 8\n",
      "0.191564730379 of whom\n",
      "0.183235500996 of alternative\n",
      "0.178879741674 > 4\n",
      "\n",
      "0.321599096091 advanced ovarian\n",
      "0.262120579698 in ovarian\n",
      "0.145882140047 6 cycles\n",
      "0.145882140047 6 cycles\n",
      "0.131257754982 ovarian cancer\n",
      "0.131257754982 ovarian cancer\n",
      "0.117326789745 liposomal doxorubicin\n",
      "0.117026081038 primary cisplatin-based\n",
      "0.0837761584325 added intravenous\n",
      "0.0605776115179 cisplatin-based intraperitoneal\n",
      "\n",
      "0.662954430757 to receive\n",
      "0.578627843475 an outcome\n",
      "0.518460684182 to optimize\n",
      "0.467199922375 trial outcome\n",
      "0.417899170524 to favorably\n",
      "0.40651089421 to develop\n",
      "0.35202455118 to an\n",
      "0.333121990384 to previous\n",
      "0.332637939912 all eligible\n",
      "0.318935684987 strategies designed\n",
      "\n",
      "0.369954564808 approach .\n",
      "0.236479664296 modified to\n",
      "0.224984502547 shown to\n",
      "0.217933173892 designed to\n",
      "0.167234378739 develop strategies\n",
      "0.150253945181 into the\n",
      "0.141577703949 an outcome\n",
      "0.137041846813 exact form\n",
      "0.120099200628 conducted that\n",
      "0.118303125684 of individuals\n",
      "\n",
      "0.993003424606 ) paclitaxel\n",
      "0.601878306657 ) plus\n",
      "0.575520017951 ) completed\n",
      "0.55362259102 and intravenous\n",
      "0.541723867091 plus intraperitoneal\n",
      "0.494174189481 intraperitoneal cisplatin\n",
      "0.467530007753 of intraperitoneal\n",
      "0.458951006558 cisplatin-based intraperitoneal\n",
      "0.458951006558 cisplatin-based intraperitoneal\n",
      "0.413926106574 pegylated liposomal\n",
      "\n",
      "0.187179095718 development of\n",
      "0.183097240321 specifically the\n",
      "0.181331875185 subset of\n",
      "0.143351602852 regimen of\n",
      "0.14143890346 development in\n",
      "0.135453184338 delivered on\n",
      "0.134621829696 toxicity of\n",
      "0.134208838542 grade 4\n",
      "0.125341700088 entry into\n",
      "0.12290921031 delivery of\n",
      "\n",
      "0.707930173022 improve the\n",
      "0.642261508525 optimize the\n",
      "0.617500624366 is a\n",
      "0.597970471302 to a\n",
      "0.596339843663 encourage the\n",
      "0.595695857195 in a\n",
      "0.471831470719 effectiveness of\n",
      "0.462790669306 specifically the\n",
      "0.451762697974 Both the\n",
      "0.413338230399 prevent its\n",
      "\n",
      "0.0443135922638 ovarian cancer\n",
      "0.0443135922638 ovarian cancer\n",
      "0.0388988891559 provocative PFS\n",
      "0.025717783297 The provocative\n",
      "0.00472488010187 exact form\n",
      "0.0 <MASK> <MASK>\n",
      "0.0 <MASK> <MASK>\n",
      "0.0 <MASK> <MASK>\n",
      "0.0 <MASK> <MASK>\n",
      "0.0 <MASK> <MASK>\n",
      "\n",
      "0.872872832708 trial outcome\n",
      "0.458962174281 trial was\n",
      "0.380799590342 an outcome\n",
      "0.369316006552 multi-center phase\n",
      "0.308097055141 trial .\n",
      "0.210822803018 2-year PFS\n",
      "0.182289860093 overall survival\n",
      "0.178439946469 eligible patients\n",
      "0.166374967166 completed 6\n",
      "0.156104397647 impact survival\n",
      "\n",
      "1.08437049363 advanced ovarian\n",
      "0.853021345586 in ovarian\n",
      "0.842934795852 cancer management\n",
      "0.699504092101 cancer ,\n",
      "0.60488134173 ovarian cancer\n",
      "0.60488134173 ovarian cancer\n",
      "0.172179861985 cisplatin-based intraperitoneal\n",
      "0.172179861985 cisplatin-based intraperitoneal\n",
      "0.111659889866 The provocative\n",
      "0.0983937436436 recurrence >\n",
      "\n",
      "0.33504077868 commonly hematologic\n",
      "0.274490415881 ) paclitaxel\n",
      "0.268397709814 worse toxicity\n",
      "0.250469646082 develop strategies\n",
      "0.249393351665 : 52\n",
      "0.200059361361 systemic toxicity\n",
      "0.19519084523 intraperitoneal cisplatin\n",
      "0.194633212174 alternative strategies\n",
      "0.193470351575 pegylated liposomal\n",
      "0.190201911225 advanced ovarian\n",
      "\n",
      "0.294025382208 treatment-related deaths\n",
      "0.265711969979 trial outcome\n",
      "0.257486322848 multi-center phase\n",
      "0.210477408392 worse toxicity\n",
      "0.190125376445 1 grade\n",
      "0.189251619349 5 treatment-related\n",
      "0.164565126066 systemic toxicity\n",
      "0.160936770816 provocative PFS\n",
      "0.127702029206 patients were\n",
      "0.124985763715 phase 2\n",
      "\n",
      "0.36970866042 a regimen\n",
      "0.328342598704 disease recurrence\n",
      "0.303242772974 a subset\n",
      "0.285855128114 and intravenous\n",
      "0.252328561771 commonly hematologic\n",
      "0.250055346091 a need\n",
      "0.240990026402 and evaluable\n",
      "0.217405323905 and median\n",
      "0.207289790045 . Treatment\n",
      "0.206521537715 . Median\n",
      "\n",
      "0.530954369017 regimen of\n",
      "0.381624298446 cycles of\n",
      "0.323679276012 regimen would\n",
      "0.322967842741 subset of\n",
      "0.27811640127 regimen .\n",
      "0.273489238855 schedule ,\n",
      "0.263650796109 pegylated liposomal\n",
      "0.256900767088 effectiveness of\n",
      "0.24249910064 chemotherapy in\n",
      "0.238475162598 cisplatin (\n",
      "\n",
      "0.63675942364 patients )\n",
      "0.576478306641 was 25\n",
      "0.522994944232 PFS )\n",
      "0.519946175385 % )\n",
      "0.519946175385 % )\n",
      "0.519946175385 % )\n",
      "0.509811038693 whom 39\n",
      "0.480371382169 hematologic )\n",
      "0.469267768312 patients (\n",
      "0.466346871189 2 )\n",
      "\n",
      "0.533574851685 trial ,\n",
      "0.436221368875 previous reports\n",
      "0.305886829807 multi-center phase\n",
      "0.287031077982 schedule ,\n",
      "0.283652049602 evaluable ,\n",
      "0.279941809547 eligible and\n",
      "0.266341412297 trial .\n",
      "0.260367036249 Overall ,\n",
      "0.248896351814 trial was\n",
      "0.218866114156 outcome ,\n",
      "\n",
      "0.494744617817 4 or\n",
      "0.35459721292 liposomal doxorubicin\n",
      "0.301686616866 exact form\n",
      "0.286908722387 shown to\n",
      "0.269182889397 a regimen\n",
      "0.26181255343 a need\n",
      "0.247347957152 plus intraperitoneal\n",
      "0.241309552076 pegylated liposomal\n",
      "0.220116433224 were without\n",
      "0.217418438539 trial outcome\n",
      "\n",
      "0.388915980985 ( day\n",
      "0.388915980985 ( day\n",
      "0.388915980985 ( day\n",
      "0.388915980985 ( day\n",
      "0.359024776171 6 cycles\n",
      "0.359024776171 6 cycles\n",
      "0.35261549191 5 treatment-related\n",
      "0.327497145497 1 grade\n",
      "0.203826076564 4 or\n",
      "0.199105987938 8 ;\n",
      "\n",
      "Long-term androgen suppression plus radiotherapy (AS+RT) is standard treatment of high-risk prostate cancer. A randomized trial, Radiation Therapy Oncology Group trial 9902, was undertaken to determine whether adjuvant chemotherapy with paclitaxel, estramustine, and etoposide (TEE) plus AS+RT would improve disease outcomes with acceptable toxicity. \n",
      "                 High-risk (prostate-specific antigen 20-100 ng/mL and Gleason score >or=7; or Stage T2 or greater, Gleason score 8, prostate-specific antigen level <100 ng/mL) nonmetastatic prostate cancer patients were randomized to AS+RT (Arm 1) vs. AS+RT plus four cycles of TEE (Arm 2). TEE was delivered 4 weeks after RT. AS continued for 2 years for both treatment arms. RT began after 8 weeks of AS began. \n",
      "                 The Radiation Therapy Oncology Group 9902 trial opened January 11, 2000. Excess thromboembolic toxicity was noted, leading to study closure October 4, 2004. A total of 397 patients were accrued, and the data for 381 were analyzable. An acute and long-term toxicity analysis was performed. The worst overall toxicities during treatment were increased for Arm 2. Of the 192 patients, 136 (71%) on Arm 2 had RTOG Grade 3 or greater toxicity compared with 70 (37%) of 189 patients on Arm 1. Statistically significant increases in hematologic toxicity (p < 0.0001) and gastrointestinal toxicity (p = 0.017) but not genitourinary toxicity (p = 0.07) were noted during treatment. Two Grade 5 complications related to neutropenic infection occurred in Arm 2. Three cases of myelodysplasia/acute myelogenous leukemia were noted in Arm 2. At 2 and 3 years after therapy completion, excess long-term toxicity was not observed in Arm 2. \n",
      "                 TEE was associated with significantly increased toxicity during treatment. The toxicity profiles did not differ at 2 and 3 years after therapy. Toxicity is an important consideration in the design of trials using adjuvant chemotherapy for prostate cancer.\n",
      "\n",
      "ec_safety_study False\n",
      "gender Male\n",
      "phase_2 False\n",
      "\n",
      "0.549639962394 Grade 5\n",
      "0.54349580757 years after\n",
      "0.54349580757 years after\n",
      "0.530935809398 score 8\n",
      "0.522643798272 % )\n",
      "0.522643798272 % )\n",
      "0.502248033391 Grade 3\n",
      "0.44601779073 weeks after\n",
      "0.438696016798 October 4\n",
      "0.434716527266 after 8\n",
      "\n",
      "0.741393114117 trial ,\n",
      "0.572571542177 trial 9902\n",
      "0.487831159271 trials using\n",
      "0.456661646465 randomized to\n",
      "0.451407116548 2 .\n",
      "0.451407116548 2 .\n",
      "0.451407116548 2 .\n",
      "0.451407116548 2 .\n",
      "0.446673946609 randomized trial\n",
      "0.415636732534 arms .\n",
      "\n",
      "0.412412086743 of 397\n",
      "0.390221315102 of 189\n",
      "0.388384477315 3 years\n",
      "0.388384477315 3 years\n",
      "0.379825933707 2 years\n",
      "0.317181265538 = 0.017\n",
      "0.307279050805 opened January\n",
      "0.231574607036 the 192\n",
      "0.216396981446 = 0.07\n",
      "0.212038598616 8 weeks\n",
      "\n",
      "0.445210072787 Long-term androgen\n",
      "0.256179031491 nonmetastatic prostate\n",
      "0.192458753977 androgen suppression\n",
      "0.186459146304 myelodysplasia/acute myelogenous\n",
      "0.163337072045 Therapy Oncology\n",
      "0.163337072045 Therapy Oncology\n",
      "0.158998632051 prostate cancer\n",
      "0.158998632051 prostate cancer\n",
      "0.158998632051 prostate cancer\n",
      "0.140954086693 using adjuvant\n",
      "\n",
      "0.538141654501 to determine\n",
      "0.500706211687 to neutropenic\n",
      "0.446410598341 the 192\n",
      "0.359312686382 The worst\n",
      "0.358620828744 to study\n",
      "0.353484609285 of 189\n",
      "0.353468036021 of 397\n",
      "0.344669529469 of high-risk\n",
      "0.342277262855 determine whether\n",
      "0.294754051832 to AS+RT\n",
      "\n",
      "0.774127171852 analysis was\n",
      "0.588499211578 using adjuvant\n",
      "0.293387518537 study closure\n",
      "0.282989301905 performed .\n",
      "0.212798742408 was performed\n",
      "0.209356660341 toxicity analysis\n",
      "0.159837823256 design of\n",
      "0.157154685391 189 patients\n",
      "0.151972853564 data for\n",
      "0.150168220352 397 patients\n",
      "\n",
      "0.639652588685 ( Arm\n",
      "0.639652588685 ( Arm\n",
      "0.601878306657 ) plus\n",
      "0.559808591508 and etoposide\n",
      "0.55540777875 with paclitaxel\n",
      "0.531292124589 ) nonmetastatic\n",
      "0.506013865397 ( AS+RT\n",
      "0.48766975918 in Arm\n",
      "0.48766975918 in Arm\n",
      "0.48766975918 in Arm\n",
      "\n",
      "0.415618935111 chemotherapy for\n",
      "0.397726089384 increased for\n",
      "0.279066635761 data for\n",
      "0.273800976863 continued for\n",
      "0.265005863411 years for\n",
      "0.189358081679 suppression plus\n",
      "0.185285892996 leukemia were\n",
      "0.165217930768 myelodysplasia/acute myelogenous\n",
      "0.157335965787 myelogenous leukemia\n",
      "0.142045040834 level <\n",
      "\n",
      "0.525172060542 in the\n",
      "0.489827043652 and the\n",
      "0.432249271675 Of the\n",
      "0.413125824167 treatment of\n",
      "0.370587883443 treatment .\n",
      "0.370587883443 treatment .\n",
      "0.359229137361 therapy .\n",
      "0.344700879513 for both\n",
      "0.341781819473 is an\n",
      "0.340060734121 . A\n",
      "\n",
      "0.498073086179 prostate-specific antigen\n",
      "0.498073086179 prostate-specific antigen\n",
      "0.425284843005 antigen 20-100\n",
      "0.324813274165 antigen level\n",
      "0.24291631818 ( prostate-specific\n",
      "0.203505761302 , prostate-specific\n",
      "0.184190410004 Long-term androgen\n",
      "0.088277786465 prostate cancer\n",
      "0.088277786465 prostate cancer\n",
      "0.088277786465 prostate cancer\n",
      "\n",
      "0.407622640499 randomized to\n",
      "0.376658674155 trials using\n",
      "0.338648870503 randomized trial\n",
      "0.328789976654 trial opened\n",
      "0.275048451094 study closure\n",
      "0.270786946309 trial 9902\n",
      "0.255577667062 disease outcomes\n",
      "0.245224905863 outcomes with\n",
      "0.197465527721 compared with\n",
      "0.186640642824 associated with\n",
      "\n",
      "1.01232406029 nonmetastatic prostate\n",
      "0.834142956851 cancer .\n",
      "0.834142956851 cancer .\n",
      "0.755213397261 prostate cancer\n",
      "0.755213397261 prostate cancer\n",
      "0.755213397261 prostate cancer\n",
      "0.751830051633 high-risk prostate\n",
      "0.739431990428 cancer patients\n",
      "0.722136500843 for prostate\n",
      "0.542479174157 Long-term androgen\n",
      "\n",
      "0.389918679468 hematologic toxicity\n",
      "0.32940568694 gastrointestinal toxicity\n",
      "0.319665097024 genitourinary toxicity\n",
      "0.310712406653 The toxicity\n",
      "0.273584817249 important consideration\n",
      "0.235152028851 long-term toxicity\n",
      "0.235152028851 long-term toxicity\n",
      "0.228590704845 greater toxicity\n",
      "0.226392141713 myelogenous leukemia\n",
      "0.2098119256 overall toxicities\n",
      "\n",
      "0.495288139729 RTOG Grade\n",
      "0.409903077039 thromboembolic toxicity\n",
      "0.302251367179 overall toxicities\n",
      "0.264319552841 Two Grade\n",
      "0.238936269786 or Stage\n",
      "0.237668904319 randomized to\n",
      "0.231815908766 had RTOG\n",
      "0.199612491092 Oncology Group\n",
      "0.199612491092 Oncology Group\n",
      "0.198794122309 trial 9902\n",
      "\n",
      "0.346951652968 and gastrointestinal\n",
      "0.339624319579 and etoposide\n",
      "0.310749039349 myelogenous leukemia\n",
      "0.274537720074 . TEE\n",
      "0.274537720074 . TEE\n",
      "0.263548878139 ) nonmetastatic\n",
      "0.263110223874 and Gleason\n",
      "0.241804872407 . RT\n",
      "0.241311842551 or Stage\n",
      "0.22787725159 and long-term\n",
      "\n",
      "0.393712023407 weeks of\n",
      "0.381624298446 cycles of\n",
      "0.333368907951 treatment of\n",
      "0.260637001407 total of\n",
      "0.254666676833 design of\n",
      "0.224269909453 etoposide (\n",
      "0.215781216668 paclitaxel ,\n",
      "0.209898151736 chemotherapy for\n",
      "0.206545549256 ) of\n",
      "0.197992245111 cases of\n",
      "\n",
      "0.646930490276 with 70\n",
      "0.532159259398 0.017 )\n",
      "0.519946175385 % )\n",
      "0.519946175385 % )\n",
      "0.513039610637 was noted\n",
      "0.512768507598 had RTOG\n",
      "0.5126341596 TEE )\n",
      "0.466687262003 0.07 )\n",
      "0.466346871189 2 )\n",
      "0.460622992197 with significantly\n",
      "\n",
      "0.533574851685 trial ,\n",
      "0.43908047602 randomized trial\n",
      "0.417447842034 randomized to\n",
      "0.364787765836 accrued ,\n",
      "0.307416046935 trial opened\n",
      "0.285642892416 trial 9902\n",
      "0.28243811474 patients ,\n",
      "0.280809964438 paclitaxel ,\n",
      "0.253347248719 9902 ,\n",
      "0.225995779455 completion ,\n",
      "\n",
      "0.543877934107 ; or\n",
      "0.51147910247 3 or\n",
      "0.436322578602 T2 or\n",
      "0.382793570235 AS+RT plus\n",
      "0.367274845538 randomized to\n",
      "0.334278244344 suppression plus\n",
      "0.312095344054 randomized trial\n",
      "0.253321147392 trial opened\n",
      "0.232793420615 determine whether\n",
      "0.218317062351 plus AS+RT\n",
      "\n",
      "0.443348444022 8 weeks\n",
      "0.402961382543 4 weeks\n",
      "0.328207755103 myelodysplasia/acute myelogenous\n",
      "0.251573079806 5 complications\n",
      "0.21450202176 myelogenous leukemia\n",
      "0.198130785481 8 ,\n",
      "0.19413401078 antigen level\n",
      "0.179153192721 Arm 1\n",
      "0.179153192721 Arm 1\n",
      "0.16779570009 11 ,\n",
      "\n"
     ]
    }
   ],
   "source": [
    "filters = model.nodes['conv'].W.eval()\n",
    "filters = np.squeeze(filters)\n",
    "filters = [filter.T for filter in filters]\n",
    "\n",
    "def activation_generator(filter, abstract):\n",
    "    for w1, w2 in zip(abstract, abstract[1:]):\n",
    "        yield np.sum(embeddings[[w1, w2]] * filter), (w1, w2)\n",
    "        \n",
    "def activations_generator(filters, abstract):\n",
    "    for filter in filters:\n",
    "        yield list(activation_generator(filter, abstract))\n",
    "        \n",
    "def show_activations(filters, abstract):\n",
    "    activations = list(activations_generator(filters, abstract))\n",
    "\n",
    "    for activation in activations:\n",
    "        for score, (w1, w2) in sorted(activation, reverse=True)[:10]:\n",
    "            print score, idx2word[w1], idx2word[w2]\n",
    "\n",
    "        print\n",
    "\n",
    "for idx in [0, 2, 7, 9, 10]:\n",
    "    print abstracts[idx]\n",
    "    print\n",
    "    for label, symbol in zip(labels, ys[:, idx]):\n",
    "        print label, class_names[label][symbol]\n",
    "    print\n",
    "    \n",
    "    show_activations(filters, abstracts_padded[idx])"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 2",
   "language": "python",
   "name": "python2"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
